InflaRx N.V. (NASDAQ: IFRX) — Perfil da empresa, notícias e dados financeiros
InflaRx specializes in developing novel therapies for inflammatory diseases using its anti-human complement factor C5a technology.
InflaRx N.V.
InflaRx N.V. (FRANKFURT:A2H7A5), (NASDAQ:IFRX) is a pioneering biotech company focused on the development of novel therapies for the treatment of inflammatory diseases using its proprietary anti-human complement factor C5a technology. With a passion for innovation, InflaRx is actively engaged in advancing a diverse pipeline of treatments aimed at addressing severe and life-threatening diseases. The company's flagship project includes developing a first-in-class anti-C5a monoclonal antibody, which has shown promise in clinical trials for conditions such as hidradenitis suppurativa, a chronic skin condition, and severe COVID-19. InflaRx's objective is to harness the power of its technology to bring transformative treatments to patients worldwide, demonstrating its commitment to improving health and making meaningful contributions to the field of medicine.
Resumo
Operações
Produtos e/ou serviços de InflaRx N.V.
- Vilobelimab (IFX-1) - a first-in-class anti-human complement factor C5a monoclonal antibody, targeting severe autoimmune and inflammatory diseases.
- Pexelizumab Collaboration - exploring the development of a complement inhibitor for cardiovascular diseases.
- COVID-19 Treatment Efforts - researching therapies using its proprietary anti-inflammatory agents.
- IFX-2 - a pipeline project aimed at treating chronic inflammatory diseases by targeting complement system components.
- Oncology Program - investigating the role of complement activation in cancer immunotherapy.
- Complement Diagnostics - developing diagnostic tools to measure complement activation in various diseases.
equipe executiva do InflaRx N.V.
- Niels C. RiedemannCo-Founder, CEO & Executive Director
- Renfeng GuoCo-Founder, Chief Scientific Officer & Executive Director
- Thomas TaapkenChief Financial Officer
- Derval O'CarrollSenior VP and Global Head of Regulatory Affairs & Compliance
- Jan MedinaHead of Investor Relations & VP
- Christian SchmidVP and Head of Legal Affairs & General Counsel
- Maria HabelVP, Head of Preclinical R&D and QC
- Kofi BoatenVP and Head of Supply Quality & Clinical Trial Supplies
- Peter HurtSenior Director and Head of Drug Safety & Pharmacovigiliance
- Daniel VetterSenior Director & Head of IT
Últimas notícias sobre a InflaRx N.V.
Principais indicadores financeiros
Resultados divulgados pela InflaRx N.V., em EUR.
- Cap. de mercado
- 260,8 mi
- Receita (TTM)
- -10,1 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 29,3 mil | -48,3 mi | -45,6 mi | |
| 165,8 mil | -52,9 mi | -46,1 mi | |
| 63,1 mil | -44,6 mi | -42,7 mi | |
| 0 | -32,2 mi | -29,5 mi |